National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Dapagliflozin (Forxiga®). HTA ID: 22030

Dapagliflozin is indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction.

 

NCPE Assessment Process Complete
Rapid review commissioned 09/05/2022
Rapid review completed 03/06/2022
Rapid Review outcome A full HTA is not recommended. The NCPE recommends that dapagliflozin be considered for reimbursement*.

 

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.